Filtered By:
Condition: Heart Disease
Procedure: Heart Transplant
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 189 results found since Jan 2013.
CZecking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol
DISCUSSION: This trial will differ from others by: (1) detailed repeated hemodynamic assessment including arteriovenous access flow and (2) by careful assessment of adequate hydration to avoid confusion between HF and water overload.PMID:35676802 | DOI:10.1177/11297298221099843
Source: The Journal of Vascular Access - June 9, 2022 Category: Surgery Authors: Jan Malik Anna Valerianova Satu Sinikka Pesickova Zdenka Hruskova Vladimira Bednarova Pavel Michalek Vladimir Polakovic Vladimir Tesar Source Type: research
Cardiovascular/Stroke Risk Assessment in Patients with Erectile Dysfunction-A Role of Carotid Wall Arterial Imaging and Plaque Tissue Characterization Using Artificial Intelligence Paradigm: A Narrative Review
Diagnostics (Basel). 2022 May 17;12(5):1249. doi: 10.3390/diagnostics12051249.ABSTRACTPURPOSE: The role of erectile dysfunction (ED) has recently shown an association with the risk of stroke and coronary heart disease (CHD) via the atherosclerotic pathway. Cardiovascular disease (CVD)/stroke risk has been widely understood with the help of carotid artery disease (CTAD), a surrogate biomarker for CHD. The proposed study emphasizes artificial intelligence-based frameworks such as machine learning (ML) and deep learning (DL) that can accurately predict the severity of CVD/stroke risk using carotid wall arterial imaging in ED ...
Source: Atherosclerosis - May 28, 2022 Category: Cardiology Authors: Narendra N Khanna Mahesh Maindarkar Ajit Saxena Puneet Ahluwalia Sudip Paul Saurabh K Srivastava Elisa Cuadrado-Godia Aditya Sharma Tomaz Omerzu Luca Saba Sophie Mavrogeni Monika Turk John R Laird George D Kitas Mostafa Fatemi Al Baha Barqawi Martin Miner Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Assessment of Hypertension, Guideline-Directed Counseling, and Outcomes in the ACHD Population
AbstractGuidelines for the diagnosis and treatment of hypertension were published by the American Heart Association (AHA) in 2017. The prevalence of hypertension in adults with congenital heart disease (ACHD) under these guidelines has yet to be characterized. We sought to assess the prevalence, impact, and provider response to hypertension under current guidelines. Data were obtained retrospectively from records of routine clinic visits over a 10 year period. Potential hypertension-related adverse outcomes including stroke, myocardial infarction, surgical intervention for aortic aneurysm, aortic dissection, atrial fibri...
Source: Pediatric Cardiology - April 5, 2022 Category: Cardiology Source Type: research
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Chronic Rejection and Atherosclerosis in Post-Transplant Cardiovascular Mortality: Two Sides of the Same Coin
Cardiovascular disease (CVD) as defined by the American Heart Association includes ischaemic heart disease, stroke, heart failure and thromboembolism [1]. Solid organ transplantation is associated with an increased risk of CVD morbidity and mortality [2], a relationship which was first observed in the context of kidney transplantation by Foley in 1998 [3]. This manifests clinically as an increased rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, non-fatal myocardial infarction, non-fatal stroke, unstable angina and heart failure [4,5].
Source: Heart, Lung and Circulation - November 27, 2021 Category: Cardiology Authors: Afolarin A. Otunla, Kumaran Shanmugarajah, Maria Lucia Madariaga, Alun H. Davies, Joseph Shalhoub Tags: Editorial Source Type: research
Fifth Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report
CONCLUSIONS: This Fifth Pedimacs Report demonstrates the continued robust growth of VADs in the pediatric community, now with over 1000 patients reported to the registry. The multiple available device types (PC, PP, IC) serve different populations with different pre-VAD risk profiles, which may account for differences in survival and AE between device types.PMID:34648810 | DOI:10.1016/j.athoracsur.2021.10.001
Source: The Annals of Thoracic Surgery - October 14, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Joseph W Rossano Christina J VanderPluym David M Peng Seth A Hollander Katsuhide Maeda Iki Adachi Ryan R Davies Kathleen E Simpson Francis Fynn-Thompson Jennifer Conway Sabrina P Law Ryan Cantor Devin Koehl Jeffrey P Jacobs Shahnawaz Amdani James K Kirkli Source Type: research
The prognostic value of the Incremental Shuttle Walk Test in Chagas cardiomyopathy
CONCLUSIONS: The ISWT is a valuable tool with potential value in the prognostic evaluation of patients with ChC.Implications for rehabilitationPatients with Chagas cardiomyopathy showed functional impairment since the early stages of heart disease.The Incremental Shuttle Walk Test (ISWT) can be a valuable and inexpensive tool in the risk stratification of the patients.The ISWT distance is an independent predictor of adverse cardiovascular event.The ISWT distance of 440m is the optimal cut-off point in the identification of patients at risk for adverse cardiovascular events.PMID:34613873 | DOI:10.1080/09638288.2021.1986580
Source: Disability and Rehabilitation - October 6, 2021 Category: Rehabilitation Authors: Matheus Ribeiro Ávila Pedro Henrique Scheidt Figueiredo Vanessa Pereira Lima Luciano Fonseca Lemos de Oliveira Lucas Frois Fernandes de Oliveira Whesley Tanor Silva Renato Guilherme Trede Filho Alessandra de Carvalho Bastone Ana Cristina Rodrigues Lacerd Source Type: research
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Acute kidney injury and risk of cardiovascular outcomes: A nationwide cohort study
CONCLUSION: Non-selected patients aged 50 years or above with AKI during admission had significantly higher one-year risk of cardiovascular event or death, especially, but not only due to heart failure, independent of age and eGFR.PMID:34489123 | DOI:10.1016/j.nefro.2021.06.007
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - September 7, 2021 Category: Urology & Nephrology Authors: Philip Andreas Schytz Paul Blanche Anders Bonde Nissen Christian Torp-Pedersen Gunnar H Gislason Karl Emil Nelveg-Kristensen Kristine Hommel Nicholas Carlson Source Type: research
